IN2013MU02145A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02145A
IN2013MU02145A IN2145MU2013A IN2013MU02145A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A IN 2145MU2013 A IN2145MU2013 A IN 2145MU2013A IN 2013MU02145 A IN2013MU02145 A IN 2013MU02145A
Authority
IN
India
Prior art keywords
monoclonal antibody
purification
provides
desired monoclonal
purity
Prior art date
Application number
Other languages
English (en)
Inventor
Sanjay Bandyopadhyay
Sanjeev Kumar Mendiratta
Avanish Kumar Singh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51655799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2013MU02145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to TW103121726A priority Critical patent/TWI596107B/zh
Priority to ARP140102380A priority patent/AR096713A1/es
Priority to KR1020157035759A priority patent/KR101683415B1/ko
Priority to SG11201509502XA priority patent/SG11201509502XA/en
Priority to US14/895,432 priority patent/US9708365B2/en
Priority to JP2015563045A priority patent/JP6039828B2/ja
Priority to EP14777867.4A priority patent/EP3013849B1/fr
Priority to CA2911874A priority patent/CA2911874A1/fr
Priority to NZ714079A priority patent/NZ714079A/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to AU2014300486A priority patent/AU2014300486B2/en
Priority to IN2145MU2013 priority patent/IN2013MU02145A/en
Priority to BR112015031196A priority patent/BR112015031196A2/pt
Priority to PCT/IN2014/000421 priority patent/WO2014207763A1/fr
Priority to CN201480031532.XA priority patent/CN105263947A/zh
Priority to MX2015016586A priority patent/MX350610B/es
Priority to EA201592192A priority patent/EA201592192A1/ru
Publication of IN2013MU02145A publication Critical patent/IN2013MU02145A/en
Priority to ZA2015/08258A priority patent/ZA201508258B/en
Priority to IL242649A priority patent/IL242649A/en
Priority to HK16105366.7A priority patent/HK1217344A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
IN2145MU2013 2013-06-25 2014-06-25 IN2013MU02145A (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
TW103121726A TWI596107B (zh) 2013-06-25 2014-06-24 單株抗體之新穎純化方法
ARP140102380A AR096713A1 (es) 2013-06-25 2014-06-24 Proceso de purificación para anticuerpos monoclonales
EA201592192A EA201592192A1 (ru) 2013-06-25 2014-06-25 Способ очистки моноклональных антител
IN2145MU2013 IN2013MU02145A (fr) 2013-06-25 2014-06-25
US14/895,432 US9708365B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
JP2015563045A JP6039828B2 (ja) 2013-06-25 2014-06-25 モノクローナル抗体の精製方法
EP14777867.4A EP3013849B1 (fr) 2013-06-25 2014-06-25 Procédé de purification pour anticorps monoclonaux
CA2911874A CA2911874A1 (fr) 2013-06-25 2014-06-25 Procede de purification pour anticorps monoclonaux
NZ714079A NZ714079A (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
KR1020157035759A KR101683415B1 (ko) 2013-06-25 2014-06-25 단일클론항체에 대한 정제 방법
AU2014300486A AU2014300486B2 (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
SG11201509502XA SG11201509502XA (en) 2013-06-25 2014-06-25 Purification process for monoclonal antibodies
BR112015031196A BR112015031196A2 (pt) 2013-06-25 2014-06-25 “processo de purificação de anticorpo monoclonal”
PCT/IN2014/000421 WO2014207763A1 (fr) 2013-06-25 2014-06-25 Procédé de purification pour anticorps monoclonaux
CN201480031532.XA CN105263947A (zh) 2013-06-25 2014-06-25 单克隆抗体的纯化工艺
MX2015016586A MX350610B (es) 2013-06-25 2014-06-25 Proceso para la purificacion de anticuerpos monoclonales.
ZA2015/08258A ZA201508258B (en) 2013-06-25 2015-11-09 Purification process for monoclonal antibodies
IL242649A IL242649A (en) 2013-06-25 2015-11-18 Purification process of monoclonal antibody
HK16105366.7A HK1217344A1 (zh) 2013-06-25 2016-05-11 單克隆抗體的純化工序

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2145MU2013 IN2013MU02145A (fr) 2013-06-25 2014-06-25

Publications (1)

Publication Number Publication Date
IN2013MU02145A true IN2013MU02145A (fr) 2015-06-05

Family

ID=51655799

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2145MU2013 IN2013MU02145A (fr) 2013-06-25 2014-06-25

Country Status (19)

Country Link
US (1) US9708365B2 (fr)
EP (1) EP3013849B1 (fr)
JP (1) JP6039828B2 (fr)
KR (1) KR101683415B1 (fr)
CN (1) CN105263947A (fr)
AR (1) AR096713A1 (fr)
AU (1) AU2014300486B2 (fr)
BR (1) BR112015031196A2 (fr)
CA (1) CA2911874A1 (fr)
EA (1) EA201592192A1 (fr)
HK (1) HK1217344A1 (fr)
IL (1) IL242649A (fr)
IN (1) IN2013MU02145A (fr)
MX (1) MX350610B (fr)
NZ (1) NZ714079A (fr)
SG (1) SG11201509502XA (fr)
TW (1) TWI596107B (fr)
WO (1) WO2014207763A1 (fr)
ZA (1) ZA201508258B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398554B (zh) * 2010-07-29 2013-06-11 Zhen Ding Technology Co Ltd 電鍍裝置
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
CA2926588C (fr) 2013-10-16 2020-07-21 Oncobiologics, Inc. Formulations de tampon pour stabilite d'anticorps amelioree
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3247718B1 (fr) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation de variants de charge dans une composition d'anticorps monoclonaux
WO2016149088A1 (fr) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Utilisation de lavages alcalins durant une chromatographie pour éliminer les impuretés
JP6968055B2 (ja) * 2015-08-21 2021-11-17 ジェネンテック， インコーポレイテッド アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法
PL3337817T3 (pl) 2015-08-21 2022-01-17 F. Hoffmann-La Roche Ag Sposób zmniejszania zawartości białek komórek gospodarza w chromatografii powinowactwa
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
MX2019000935A (es) 2016-08-16 2019-07-04 Regeneron Pharma Metodos para cuantificar anticuerpos individuales de una mezcla.
CN109923411B (zh) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 用于色谱数据分析的方法和系统
CN109963560A (zh) * 2016-10-28 2019-07-02 默沙东公司 用于除去酪氨酸硫酸化抗体变体的纯化方法、经纯化的组合物
CA3047530A1 (fr) 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Procedes ameliores pour augmenter la productivite d'anticorps dans une culture de cellules de mammifere et minimiser l'agregation pendant des processus de formulation en aval, procedes de formulation et formulations d'anticorps stables obtenus a partir de ceux-ci
KR102087823B1 (ko) * 2017-05-16 2020-03-13 에이치케이이노엔 주식회사 친화성 크로마토그래피를 이용한 항체 또는 항체절편 정제 방법
EP3431168A1 (fr) * 2017-07-19 2019-01-23 Bayer Aktiengesellschaft Élimination de médicament non lié après accouplement conjugué anticorps-médicament
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CN110128538B (zh) * 2018-02-09 2022-08-26 鲁南制药集团股份有限公司 一种纯化抗cd20人鼠嵌合单克隆抗体的方法
US11155575B2 (en) 2018-03-21 2021-10-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbent, devices and methods
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
EP3823594A1 (fr) 2018-07-19 2021-05-26 Ichnos Sciences S.A. Formulation d'anticorps liquide
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
CN111072773A (zh) * 2018-10-19 2020-04-28 菲鹏生物股份有限公司 抗体的纯化方法、抗体和应用
EP3643322A1 (fr) * 2018-10-26 2020-04-29 Mabion SA Formulation de ligand anti cd20 à faible agrégat
WO2020084503A1 (fr) 2018-10-26 2020-04-30 Cadila Healthcare Limited Composition comprenant un anticorps ayant un niveau réduit de variants basiques de celui-ci
CN109320611B (zh) * 2018-10-31 2022-06-03 鼎康(武汉)生物医药有限公司 一种人鼠嵌合单克隆抗体生物类似药的纯化方法
CN109336969B (zh) * 2018-11-09 2021-02-12 杭州奕安济世生物药业有限公司 一种抗体的纯化方法
CN114729003A (zh) 2019-11-22 2022-07-08 莫佛塞斯公司 提高离子交换色谱过程中抗体产率的方法
WO2021139720A1 (fr) * 2020-01-08 2021-07-15 信达生物制药(苏州)有限公司 Procédé de purification d'adalimumab et composition stable associée
KR102154952B1 (ko) * 2020-02-21 2020-09-10 프레스티지바이오로직스 주식회사 아달리무맙의 Non-Protein A 정제방법
WO2022245306A1 (fr) * 2021-05-20 2022-11-24 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Purification de protéines par chromatographie d'affinité
CN114133446A (zh) * 2021-12-31 2022-03-04 方坦思(上海)生物医药有限公司 单克隆抗体的纯化方法
CN115491328A (zh) * 2022-08-31 2022-12-20 深圳市卫光生物制品股份有限公司 一种大肠杆菌表达蛋白及其表达纯化方法
EP4335869A1 (fr) 2022-09-07 2024-03-13 Bio T Biyoteknoloji Cozumleri Ve Uretim Anonim Résine et colonne de chromatographie qui épure des anticorps avec de petits peptides résistant aux protéases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
SI1308456T1 (sl) 1998-05-06 2008-02-29 Genentech Inc Ciscenje protiteles z ionsko izmenjevalno kromatografijo
PT1308455E (pt) 1998-05-06 2006-08-31 Genentech Inc Composicao compreendendo anticorpos anti-her2
ATE274522T1 (de) * 1998-06-01 2004-09-15 Genentech Inc Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
EP1614693A4 (fr) 2003-03-31 2006-07-19 Kirin Brewery Purification d'un anticorps monoclonal humain et d'un anticorps polyclonal humain
WO2005000898A2 (fr) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Purification et synthese preferentielle de molecules de liaison
SE0400501D0 (sv) 2004-02-27 2004-02-27 Amersham Biosciences Ab Antibody purification
HUE049797T2 (hu) 2005-03-11 2020-10-28 Wyeth Llc Gyenge megoszlási kromatográfiás eljárás
CN101365722A (zh) 2005-06-17 2009-02-11 艾兰制药国际有限公司 纯化抗Aβ抗体的方法
WO2007109163A2 (fr) 2006-03-16 2007-09-27 Amgen Inc Tampon de lavage et procédé d'utilisation correspondant
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
MX2009002576A (es) 2006-09-08 2009-03-20 Wyeth Corp Lavado de arginina en purificacion de proteina utilizando cromatografia de afinidad.
EP2212432A4 (fr) * 2007-10-22 2011-10-19 Schering Corp Anticorps anti-vegf entièrement humains et leurs procédés d'utilisation
WO2010030222A1 (fr) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Séparation protéine-agrégat améliorée avec des échangeurs d'anions multimodaux en présence de zwitterions exclus de la protéine
US20100069617A1 (en) 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal by mixed mode chromatography on hydrophobic interaction media in the presence of protein-excluded zwitterions
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
CN104744560A (zh) 2009-10-20 2015-07-01 Abbvie公司 使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
EP2519536A4 (fr) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr Purification des protéines par échange d'ions
AU2011208659B2 (en) 2010-01-22 2015-05-28 Boehringer Ingelheim International Gmbh Chromatographic method for purifying Fc-containing proteins
CN102179237A (zh) * 2010-04-26 2011-09-14 无锡加莱克色谱科技有限公司 一种用于分离、提纯单克隆抗体和抗体球蛋白的亲和色谱填料及其制备方法
JP6023715B2 (ja) * 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
EP2649016B1 (fr) 2010-12-06 2020-06-10 Pall Corporation Procédés de traitement continu pour produits biologiques
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
EP2723759A4 (fr) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr Purification de protéine chimérique
WO2013066707A1 (fr) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Procédé de chromatographie permettant de décomposer des agrégats d'anticorps hétérogènes
WO2013075740A1 (fr) 2011-11-23 2013-05-30 Sanofi Procédé de purification d'anticorps
EP4026596A1 (fr) * 2013-03-14 2022-07-13 Amgen, Inc Élimination de ligand de purification par affinité de fuite
WO2014209508A1 (fr) * 2013-05-13 2014-12-31 Medimmune, Llc Séparation de multimères d'anticorps polyclonaux de recombinaison avec une séparation minimale des monomères
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法

Also Published As

Publication number Publication date
JP2016525500A (ja) 2016-08-25
MX2015016586A (es) 2016-03-16
TW201512217A (zh) 2015-04-01
NZ714079A (en) 2017-05-26
US20160115195A1 (en) 2016-04-28
KR20160003311A (ko) 2016-01-08
WO2014207763A1 (fr) 2014-12-31
AR096713A1 (es) 2016-01-27
AU2014300486B2 (en) 2016-06-30
MX350610B (es) 2017-09-11
ZA201508258B (en) 2017-03-29
TWI596107B (zh) 2017-08-21
CN105263947A (zh) 2016-01-20
SG11201509502XA (en) 2015-12-30
HK1217344A1 (zh) 2017-01-06
CA2911874A1 (fr) 2014-12-31
IL242649A (en) 2016-03-31
KR101683415B1 (ko) 2016-12-06
US9708365B2 (en) 2017-07-18
EP3013849A1 (fr) 2016-05-04
EP3013849B1 (fr) 2017-09-13
JP6039828B2 (ja) 2016-12-07
EA201592192A1 (ru) 2016-07-29
AU2014300486A1 (en) 2015-11-26
BR112015031196A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
IN2013MU02145A (fr)
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2015015482A (es) Proceso continuo de multiples etapas para purificar anticuerpos.
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX364908B (es) Purificación de proteínas usando amortiguador bis-tris.
MX2023008870A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
EP3280444A4 (fr) Procédés de purification d'anticorps hétérodimères multispécifiques mélangés à des espèces d'anticorps homodimères parentaux
WO2018162557A3 (fr) Procédé de purification de protéines à l'aide de silicate
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EA201400273A1 (ru) Способ снижения тромбоэмболического потенциала композиции, содержащей полученный из плазмы иммуноглобулин
SG10201806643WA (en) Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
MX2016000181A (es) Explicacion de la optimizacion de entrada de la cromatografia de intercambio ionico.
EP3575279A4 (fr) Procédé de production d'alcool à haute concentration
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
SG11201802997WA (en) Affinity chromatography carrier and method for purifying biological substance
EP3560956A3 (fr) Procédés de traitement de maladies inflammatoires
MY197993A (en) Method for protein purification
MX369054B (es) Detección de moléculas de ácido nucleico.
MX2015013182A (es) Purificacion analitica basada en la afinidad de compuestos bioterapeuticos para el control de bioprocesos.
MX2019011343A (es) Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
JOP20200106A1 (ar) جسم مضاد أحادي النسيلة مضاد لـ il-5r?
EP4239329A3 (fr) Procédé et appareil